Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Aug 2011

Wagle Nikhil, Emery Caroline, Berger Michael F, Davis Matthew J, Sawyer Allison, Pochanard Panisa, Kehoe Sarah M, Johannessen Cory M, Macconaill Laura E, Hahn William C, Meyerson Matthew, Garraway Levi A

Abstract excerpt

A detailed understanding of the mechanisms by which tumors acquire resistance to targeted anticancer agents should speed the development of treatment strategies with lasting clinical efficacy. RAF inhibition in BRAF-mutant melanoma exemplifies the promise and challenge of many targeted drugs; although response rates are high, resistance invariably develops. Here, we articulate overarching principles of resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fatal Outcome
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Precision Medicine

Share to Skin Neoplasms

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 21383288
DOI: 10.1200/JCO.2010.33.2312
PMCID: PMC3157968

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.PMID 21383288Read ↗

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Semantic proximity Read ↗

MEK1 mutations confer resistance to MEK and B-RAF inhibitionSemantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.Semantic proximity Read ↗

The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.